Evidence map›Paper›PMID 42443950›Full record

ArticleJournal of ovarian research2026

Modeling fertile window differences across the reproductive lifespan with quantitative urine hormone monitoring of the menstrual cycle.

Thomas P Bouchard, Richard J Fehring, Maria Meyers, Theresa Stujenske, Louise Boychuk, Amanda Smith, Katherine Schweinsberg, Bruno Scarpa, Mary Schneider

Abstract read
In one paragraph

Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas P BouchardDepartment of Family Medicine, University of Calgary, 108-30 Springborough Blvd SW, Calgary, AB, T3H 0N9, Canada. tbouchar@ucalgary.ca.
Richard J FehringCollege of Nursing, Marquette University, Milwaukee, USA.
Maria MeyersMarquette Method Professional Association, Milwaukee, USA.
Theresa StujenskeSchool of Nursing, Duquesne University, Pittsburgh, USA.
Louise BoychukMarquette Method Professional Association, Milwaukee, USA.
Amanda SmithMarquette Method Professional Association, Milwaukee, USA.
Katherine SchweinsbergMarquette Method Professional Association, Milwaukee, USA.
Bruno ScarpaDepartment of Statistical Sciences, University of Padua, Padua, Italy.
Mary SchneiderCollege of Nursing, Marquette University, Milwaukee, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReproductive hormones of the fertile window are often referenced to women in regular cycles, but this may not be representative of the hormonal profiles of women in different circumstances like polycystic ovarian syndrome, the postpartum period, and the perimenopause transition. This observational cohort study sought to identify the variability in the reproductive hormones in various clinical circumstances and to establish potential thresholds for each category based on hormone measurements with the Mira urinary hormone monitor.

resultsA total of 57 women (ages 22-51) in various circumstances (regular cycles, polycystic ovarian syndrome, postpartum and perimenopause) tracked Mira urine hormone measurements (estrone-3-glucuronide, luteinizing hormone, pregnanediol glucuronide), contributing 444 cycles of data. Using additive mixed models, hormone values were stratified by the four different reproductive categories. The perimenopause and polycystic ovarian syndrome groups demonstrated relative hypoestrogenic states, while the perimenopause group showed low luteal pregnanediol glucuronide and the polycystic ovarian syndrome/polyendocrine metabolic ovarian syndrome (PCOS/PMOS) group showed high luteal pregnanediol glucuronide. The perimenopause group had significantly higher luteinizing hormone values throughout the whole cycle.

conclusionThe fertile window hormone thresholds vary depending on a woman's specific reproductive category. Women in different circumstances should not necessarily use the same hormonal thresholds for the fertile window and ovulation. A larger dataset with ultrasound correlation to ovulation is required to delineate the fertile window with more precision. Hormone differences across the menstrual cycle could be used for targeted treatments in polycystic ovarian syndrome and perimenopause women.

Indexed as

FertilityMenstrual CycleReproductionAdultEstroneFemaleHumansLuteinizing HormoneMiddle AgedPolycystic Ovary SyndromePregnanediolYoung AdultEstroneestrone-3-glucuronideLuteinizing HormonePregnanediolpregnanediol-3 alpha-glucuronideEstrone-3-glucuronide (E13G)luteinizing hormone (LH)Menstrual CycleOvulationPregnanediol glucuronide (PDG)

Identifiers

PMID42443950
PMCPMC13660213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.